Promising combo for Tough-to-Treat hodgkin lymphoma shows progress
NCT ID NCT02227199
First seen Nov 18, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tested a new combination of a targeted drug (brentuximab vedotin) with standard chemotherapy for people whose Hodgkin lymphoma returned or didn't respond to treatment. The goal was to find the safest dose and see how many patients achieved complete remission. 45 adults took part, and the results help guide future treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.